株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

分子診断:世界市場の規模・戦略・予測 (2016-2019年)

Molecular Diagnostics - Global Market Size, Strategies and Forecasts - 2015 to 2019

発行 Howe Sound Research 商品コード 333704
出版日 ページ情報 英文 228 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。
Back to Top
分子診断:世界市場の規模・戦略・予測 (2016-2019年) Molecular Diagnostics - Global Market Size, Strategies and Forecasts - 2015 to 2019
出版日: 2016年01月18日 ページ情報: 英文 228 Pages
概要

当レポートでは、世界の分子診断の市場について調査し、分子診断の定義、産業構造と主な参入事業者、主要事業者の市場シェア、市場成長の推進因子・阻害因子の分析、市場および技術の発展動向、近年の企業および企業間の取り組み、地域/国・検査区分別の市場規模の推移と予測などをまとめています。

第1章 イントロダクション・市場の定義

第2章 市場概要

  • 市場参入企業
  • 市場区分
  • 産業構造
  • 主要企業のプロファイル
  • 主要企業の市場シェア

第3章 市場動向

  • 成長促進因子
  • 成長抑制因子
  • 計測化と自動化
  • 診断技術の発展

第4章 分子診断の近年の発展

  • CollabRx・GeneInsight:臨床遺伝子シーケンシングのサービスで協力
  • Thermo Fisher:Life Technologiesを買収
  • DiaTech Oncology:テネシー州のメディカルラボへの投資を検討
  • CardioDx:College of American Pathologists (CAP) の認証取得
  • LipoScience: 心血管系疾患管理のためのリポタンパク質分析を提供予定
  • DiaTech Oncology:増資の発表
  • Inostics' Lab:CLIAの認定取得
  • 開発中の自宅用迅速大腸癌検査
  • 20分でMicroRNAを検出するPOC検査デバイス
  • Johnson & JohnsonによるOrtho Clinical Diagnosticsのスピンオフの可能性、など

第5章 国別市場規模:北米

  • 米国
  • カナダ
    • 分子診断による感染症検査:診断数・価格・収益
    • 分子診断による遺伝子検査:診断数・価格・収益
    • 分子診断による癌検査:診断数・価格・収益
    • 総市場:診断数・価格・収益

第6章 国別市場規模:欧州

  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • スイス
  • チェコ共和国
  • ベルギー
  • ロシア
  • 欧州のその他の地域・旧ソ連
    • 分子診断による感染症検査:診断数・価格・収益
    • 分子診断による遺伝子検査:診断数・価格・収益
    • 分子診断による癌検査:診断数・価格・収益
    • 総市場:診断数・価格・収益

第7章 国別市場規模:アジア太平洋

  • 中国
  • 日本
  • 韓国
  • インド
  • オーストラリア
  • その他
    • 分子診断による感染症検査:診断数・価格・収益
    • 分子診断による遺伝子検査:診断数・価格・収益
    • 分子診断による癌検査:診断数・価格・収益
    • 総市場:診断数・価格・収益

第8章 国別市場規模:ラテンアメリカ・アフリカ・中東

  • ブラジル
  • メキシコ
  • ラテンアメリカのその他の地域
  • アフリカ・中東
    • 分子診断による感染症検査:診断数・価格・収益
    • 分子診断による遺伝子検査:診断数・価格・収益
    • 分子診断による癌検査:診断数・価格・収益
    • 総市場:診断数・価格・収益

第9章 世界市場:サマリー

  • 世界市場
    • 分子診断による感染症検査:診断数・価格・収益
    • 分子診断による遺伝子検査:診断数・価格・収益
    • 分子診断による癌検査:診断数・価格・収益
    • 総市場:診断数・価格・収益

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

A market that just keeps on growing. Molecular Diagnostics is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • personalized medicine
  • pharmacogenomics
  • pathogen evolution
  • next generation sequencing
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

The report data is designed to be used! The unit volumes of tests performed is presented. Use our pricing scenarios or use your own. Project your market share and your price to reliably generate revenue forecasts or understand your own current market share position. Detailed Market Forecasts provide Price, Volume and Revenue Forecasts individually broken out by year for Infectious Disease, Genetic Testing, Oncology Testing.

In addition customization work, assistance and support is included with every report.

"Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2016 to 2019" provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2015 United States Medicare Fee Payment Schedules to help understand test pricing in detail. See lists of all current FDA Approved Molecular Diagnostic Tests. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions. Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

" This is an impressive piece of work." Doug Buchanan, Managing Director and CEO BC Biomedical Laboratories Ltd.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Make investment decisions and valuations with confidence using the latest data. Be completely up to date with over 250 summaries of industry developments.

Table of Contents

1. Introduction and Market Definition

  • 1.1 What is Molecular Diagnostics
  • 1.2 The Diagnostics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size.
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. Market Overview

  • 2.1 Market Participants
    • 2.1.1 Supplier/pharmaceutical
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab.
    • 2.1.7 Physician lab
    • 2.1.8 Audit body
  • 2.2 Market Segments
    • 2.2.1 Traditional Market Segmentation
    • 2.2.2 Laboratory Focus and Segmentation
  • 2.3 Industry Structure
    • 2.3.1 Hospital Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.3 Physician Office Lab's
    • 2.3.4 Physician's and POCT
  • 2.4 Profiles of Key MDx Companies
    • 2.4.1 Roche Molecular Diagnostics
    • 2.4.2 Illumina
    • 2.4.3 Hologic
    • 2.4.4 Agilent/Dako
    • 2.4.5 Qiagen
    • 2.4.6 Myriad Genetics
    • 2.4.7 Becton, Dickinson & Co.
    • 2.4.8 Abbott Laboratories
    • 2.4.9 Cepheid
    • 2.4.10 Genomic Health
    • 2.4.11 Grifols
    • 2.4.12 bioMérieux
    • 2.4.13 Foundation Medicine
    • 2.4.14 Agendia
    • 2.4.15 Thermo Fisher
    • 2.4.16 Signal Genetics LLC
    • 2.4.17 Siemens Healthcare
  • 2.5 Market Shares of Key MDx Players - Analysis

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 New Diagnostic Definitions Create New Markets
    • 3.1.2 Aging Population a Boon for Diagnostics.
    • 3.1.3 Pharmacogenomics Drives Further Growth.
    • 3.1.4 Point of Care Testing can increase demand
    • 3.1.5 Liquid Biopsy
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Testing usage analysis curtailing growth
    • 3.2.4 Wellness has a downside
    • 3.2.5 Point of Care Testing
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role.
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 POCT/Self Testing Disruptive Force
    • 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.5 CGES Testing, A Brave New World.
    • 3.4.6 Biochips/Giant magneto resistance based assay

4. Molecular Diagnostics Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
  • 4.3 CollabRx and GeneInsight to Collaborate on Service for Clinical
  • 4.48 Transgenomic Closes Public Offering of Stock, Warrants
  • 4.49 Qiagen Discloses $114.2M Price Tag for Enyzmatics Acquisition
  • 4.51 GenomeDx Biosciences Implements Clarity LIMS
  • 4.52 Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.53 Lifecode Receives CAP Accreditation, Discloses Funding
  • 4.54 Baylor College of Medicin, Miraca Holdings finalize joint venture
  • 4.55 23andMe Gets FDA Clearance to Market Bloom Syndrome Carrier Test
  • 4.57 Trinity Biotech Revenues Grow by 15%
  • 4.58 Google's Latest Healthcare Initiative
  • 4.60 Agena Bioscience Launches Smaller Format MassArray
  • 4.61 QuantRx® Biomedical Provides Update on Technological Progress
  • 4.62 The Journal of Molecular Diagnostics Publishes Special Article
  • 4.63 Caprion Licenses Indi's Xpresys as Part of Larger Clinical Push
  • 4.64 MDxHealth's ConfirmMDx Genes Detect Prostate Cancer
  • 4.65 Atossa Genetics Announces That Its Subsidiary The National Reference Laboratory for Breast Health Has Received Accreditation
  • 4.66 Nuclea Bio Plans Entry into Clinical Proteomics
  • 4.67 Personal Genome Diagnostics Aims for FDA Clearance
  • 4.68 Enzo Biochem Announces New Molecular Platform
  • 4.69 Multiplicom, Premaitha Develop CE-IVDs
  • 4.70 Regulating the Next Generation of Genetic Testing
  • 4.71 BioReference Laboratories, Inc. Launches an Advanced Tumor Sequencing Program
  • 4.72 Cytogenetics Become First Certified Lab to Offer Microarray Testing
  • 4.73 Results Support Clinical Validity of Quantose IGT(TM) Diabetes Test
  • 4.74 Accelerate Diagnostics' 2014 Revenues Rise Sharply
  • 4.75 NanoString's Q4 Revenues Jump 54 Percent
  • 4.76 New Aussie Firm Life Letters Launches Carrier, PGx Testing for Consumers
  • 4.77 HTG Molecular Reports 50 Percent Increase in 2014 Revenues
  • 4.80 Genomic Vision, Quest Extend Pact for Molecular Combing Technology
  • 4.81 ACT Genomics Raises $8M in Private Funding Round
  • 4.82 NGS-based Cancer MDx Firm Lifecode Raises $20.5M, Receives CAP Accreditation
  • 4.83 Invitae Goes Public with $101.6M Offering
  • 4.84 Quidel Q4 Revenues Grow 27 Percent on Infectious Disease Sales
  • 4.85 Rosetta Signs Deal to Promote Precipio's Cancer Diagnostics
  • 4.86 Premaitha Iona NIPT Lands CE Mark
  • 4.87 Sera Increases Series B Round to $25M with $5M from Gates Foundation
  • 4.88 T2 Biosystems Inks $8.5M Lyme Disease Dx Deal with Canon US Life Sciences
  • 4.89 Invitae Amends IPO Filing Targeting up to $92.3M
  • 4.90 Biofortuna Closes $2.2M Funding Round
  • 4.91 Roche MDx Sales Help Drive 2014 Diagnostics Revenues up 3 Percent
  • 4.92 AltheaDx Increases Target Amount on Proposed IPO to $74.3M
  • 4.93 BioMerieux 2014 Revenues Increase 7 Percent
  • 4.94 Cypher Genomics and Sequenom Announce Development Agreement
  • 4.95 Abcam to Acquire Firefly BioWorks for $28M
  • 4.97 Human Longevity, Genentech Ink Deal to Sequence Thousands of Genomes
  • 4.98 GenMark Projects 52 Percent Growth in Q4 Revenues
  • 4.99 Amarantus Acquires DioGenix for up to $10.9M
  • 4.100 Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake
  • 4.101 DiaCarta Raises $8M in Series A Round
  • 4.102 Epic Sciences' Cancer Dx Laboratory Receives CLIA Certification
  • 4.103 Adaptive Biotechnologies Acquires Sequenta
  • 4.104 Aegis Sciences Acquires MDx Firm Diagnovus
  • 4.105 Interleukin Genetics Secures $10M in Financing
  • 4.106 Premaitha NIPT Test Receives ISO Certification
  • 4.107 HTG Molecular Diagnostics Files for IPO of up to $60M
  • 4.108 CardioDx Raises $35M.
  • 4.109 MolecularMD Receives CAP Accreditation
  • 4.110 14M Genomics Secures £12.5M Equity Financing for Oncology Dx
  • 4.111 Protagen Closes First Part of Financing Round
  • 4.112 Glyconics Inks Exclusive Licensing Deal
  • 4.113 Great Basin Scientific Begins Trial for Staph Assay
  • 4.114 Response Genetics Receives NYS Approval for Cancer Test
  • 4.115 Claritas Genomics Adopts NextCode Health Platform to Interpret NGS Tests
  • 4.116 FDA Clears Quidel's MDx for Bordetella Pertussis
  • 4.117 FDA Clears Additional Flu Strains for Focus' MDx Assay
  • 4.118 Novacyt Raises $3.8M in Private Equity
  • 4.119 Good Start Genetics Licenses PGS Technology from Johns Hopkins
  • 4.120 Metamark's Cambridge Lab Receives CAP Accreditation
  • 4.121 Australia's VCGS Inks Deal with Illumina to Develop NIPT
  • 4.123 Personalized Medicine Firm Newtopia Garners Investment from Bloom Burton
  • 4.124 Roche to Acquire Ariosa Diagnostics
  • 4.125 Biological Dynamics secures $26.8M Series C for further molecular diagnostics growth
  • 4.126 NEO New Oncology begins study on molecular diagnostics for lung cancer patients
  • 4.127 Qvella raises $20 million U.S. Series A round
  • 4.128 Enzo Biochem Demonstrates Greater Sensitivity of Its AmpiProbe™ Platform for Molecular Diagnostics

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 5.1.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 5.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 5.1.4 MDx Total - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 5.2.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 5.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 5.2.4 MDx Total - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.1.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.1.4 MDx Total - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.2.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.2.4 MDx Total - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.3.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.3.4 MDx Total - Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.4.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.4.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.4.4 MDx Total - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.5.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.5.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.5.4 MDx Total - Volumes, Prices, Revenues
  • 6.6 Switzerland
    • 6.6.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.6.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.6.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.6.4 MDx Total - Volumes, Prices, Revenues
  • 6.7 Czech Republic
    • 6.7.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.7.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.7.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.7.4 MDx Total - Volumes, Prices, Revenues
  • 6.8 Belgium
    • 6.8.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.8.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.8.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.8.4 MDx Total - Volumes, Prices, Revenues
  • 6.9 Russia
    • 6.9.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.9.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.9.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.9.4 MDx Total - Volumes, Prices, Revenues
  • 6.10 Remainder of Europe and Former Soviet Union
    • 6.10.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 6.10.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 6.10.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 6.10.4 MDx Total - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.1.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.1.4 MDx Total - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.2.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.2.4 MDx Total - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.3.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.3.4 MDx Total - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.4.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.4.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.4.4 MDx Total - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.5.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.5.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.5.4 MDx Total - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 7.6.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 7.6.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 7.6.4 MDx Total - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil .
    • 8.1.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 8.1.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 8.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 8.1.4 MDx Total - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 8.2.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 8.2.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 8.2.4 MDx Total - Volumes, Prices, Revenues
  • 8.3 Remainder of Latin America
    • 8.3.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 8.3.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 8.3.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 8.3.4 MDx Total - Volumes, Prices, Revenues
  • 8.4 Africa & The Middle East
    • 8.4.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 8.4.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 8.4.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 8.4.4 MDx Total - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global Market
    • 9.1.1 MDx Infectious Disease - Volumes, Prices, Revenues
    • 9.1.2 MDx Genetic Testing - Volumes, Prices, Revenues
    • 9.1.3 MDx Oncology Testing - Volumes, Prices, Revenues
    • 9.1.4 MDx Total - Volumes, Prices, Revenues

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National L imit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Clinical Laboratory Departments and Segments
  • Table 4 Laboratory Management Focus - Different Approaches
  • Table 5 Key Segmentation Variables Going Forward
  • Table 6 Five Factors Driving Growth
  • Table 7 Four Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends.
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 11 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 12 MDx Oncology - Volume Price and Revenue Forecast
  • Table 13 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 14 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 15 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 16 MDx Oncology - Volume Price and Revenue Forecast
  • Table 17 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 18 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 19 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 20 MDx Oncology - Volume Price and Revenue Forecast
  • Table 21 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 22 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 23 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 24 MDx Oncology - Volume Price and Revenue Forecast
  • Table 25 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 26 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 27 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 28 MDx Oncology - Volume Price and Revenue Forecast
  • Table 29 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 30 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 31 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 32 MDx Oncology - Volume Price and Revenue Forecast
  • Table 33 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 34 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 35 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 36 MDx Oncology - Volume Price and Revenue Forecast
  • Table 37 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 38 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 39 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 40 MDx Oncology - Volume Price and Revenue Forecast
  • Table 41 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 42 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 43 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 44 MDx Oncology - Volume Price and Revenue Forecast
  • Table 45 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 46 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 47 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 48 MDx Oncology - Volume Price and Revenue Forecast
  • Table 49 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 50 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 51 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 52 MDx Oncology - Volume Price and Revenue Forecast
  • Table 53 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 54 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 55 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 56 MDx Oncology - Volume Price and Revenue Forecast
  • Table 57 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 58 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 59 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 60 MDx Oncology - Volume Price and Revenue Forecast
  • Table 61 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 62 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 63 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 64 MDx Oncology - Volume Price and Revenue Forecast
  • Table 65 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 66 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 67 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 68 MDx Oncology - Volume Price and Revenue Forecast
  • Table 69 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 70 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 71 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 72 MDx Oncology - Volume Price and Revenue Forecast
  • Table 73 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 74 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 75 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 76 MDx Oncology - Volume Price and Revenue Forecast
  • Table 77 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 78 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 79 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 80 MDx Oncology - Volume Price and Revenue Forecast
  • Table 81 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 82 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 83 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 84 MDx Oncology - Volume Price and Revenue Forecast
  • Table 85 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 86 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 87 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 88 MDx Oncology - Volume Price and Revenue Forecast
  • Table 89 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 90 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 91 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 92 MDx Oncology - Volume Price and Revenue Forecast
  • Table 93 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 94 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 95 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 96 MDx Oncology - Volume Price and Revenue Forecast
  • Table 97 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 98 MDx Infectious Disease - Volume Price and Revenue Forecast
  • Table 99 MDx Genetic Testing - Volume Price and Revenue Forecast
  • Table 100 MDx Oncology - Volume Price and Revenue Forecast
  • Table 101 Molecular Diagnostics - Volume Price and Revenue Forecast
  • Table 102 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 Chart of Market Shares of Key MDx Companies
  • Figure 3 Percentage of World Population Over 65
Back to Top